dc.creator | Santos García, Diego | es |
dc.creator | Deus, Teresa de | es |
dc.creator | Cores, Carlos | es |
dc.creator | Canfield, Hector | es |
dc.creator | Paz González, José M. | es |
dc.creator | Martínez Miró, Cristina | es |
dc.creator | Mir Rivera, Pablo | es |
dc.date.accessioned | 2022-11-24T08:12:25Z | |
dc.date.available | 2022-11-24T08:12:25Z | |
dc.date.issued | 2021-06-30 | |
dc.identifier.citation | Santos-García, D., Deus, T.d., Cores, C., Canfield, H., Paz González, J.M., Martínez Miró, C. y Mir Rivera, P. (2021). Predictors of global non-motor symptoms burden progression in Parkinson’s disease. Results from the COPPADIS cohort at 2-year follow-up. Journal of personalized medicine, 11 (7), 626. https://doi.org/10.3390/jpm11070626. | |
dc.identifier.issn | 2075-4426 | es |
dc.identifier.uri | https://hdl.handle.net/11441/139738 | |
dc.description.abstract | Background and Objective: Non-motor symptoms (NMS) progress in different ways between Parkinson’s disease (PD) patients. The aim of the present study was to (1) analyze the change in global NMS burden in a PD cohort after a 2-year follow-up, (2) to compare the changes with a control group, and (3) to identify predictors of global NMS burden progression in the PD group. Material and Methods: PD patients and controls, recruited from 35 centers of Spain from the COPPADIS cohort from January 2016 to November 2017, were followed-up with after 2 years. The Non-Motor Symptoms Scale (NMSS) was administered at baseline (V0) and at 24 months ± 1 month (V2). Linear regression models were used for determining predictive factors of global NMS burden progression (NMSS total score change from V0 to V2 as dependent variable). Results: After the 2-year follow-up, the mean NMS burden (NMSS total score) significantly increased in PD patients by 18.8% (from 45.08 ± 37.62 to 53.55 ± 42.28; p < 0.0001; N = 501; 60.2% males, mean age 62.59 ± 8.91) compared to no change observed in controls (from 14.74 ± 18.72 to 14.65 ± 21.82; p = 0.428; N = 122; 49.5% males, mean age 60.99 ± 8.32) (p < 0.0001). NMSS total score at baseline (β = −0.52), change from V0 to V2 in PDSS (Parkinson’s Disease Sleep Scale) (β = −0.34), and change from V0 to V2 in NPI (Neuropsychiatric Inventory) (β = 0.25) provided the highest contributions to the model (adjusted R-squared 0.41; Durbin-Watson test = 1.865). Conclusions: Global NMS burden demonstrates short-term progression in PD patients but not in controls and identifies worsening sleep problems and neuropsychiatric symptoms as significant independent predictors of this NMS progression. | es |
dc.format | application/pdf | es |
dc.format.extent | 25 p. | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | Journal of personalized medicine, 11 (7), 626. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Mood | es |
dc.subject | Non-motor symptoms | es |
dc.subject | Parkinson’s disease | es |
dc.subject | Progression | es |
dc.subject | Quality of life | es |
dc.title | Predictors of global non-motor symptoms burden progression in Parkinson’s disease. Results from the COPPADIS cohort at 2-year follow-up | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.mdpi.com/2075-4426/11/7/626 | es |
dc.identifier.doi | 10.3390/jpm11070626 | es |
dc.journaltitle | Journal of personalized medicine | es |
dc.publication.volumen | 11 | es |
dc.publication.issue | 7 | es |
dc.publication.initialPage | 626 | es |
dc.contributor.funder | Fundación Española de Ayuda a la Investigación en Parkinson y otras Enfermedades Neuro-degenerativas | es |